Daivonex

Phase 1Small molecule

LEO Pharma

Daivonex is one of 60 small molecule programs targeting Psoriasis Vulgaris. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psoriasis VulgarisActive, not recruiting

PsoriasisActive, not recruiting

Psoriasis VulgarisPhase 1

Active, not recruiting

PsoriasisPhase 1

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Stelara

Johnson & Johnson

Preclinical

37 3

Taltz

Eli Lilly

Preclinical

20 4

Bimzelx

UCB

Preclinical

17 5

Humira

CCelltrion

Preclinical

42 6

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 7

Raptiva

Roche

Preclinical

10 8

Remicade

OOrganon and Co

Preclinical

20 9

Siliq

BBausch Health Americas, Inc.

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis4 trials

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test

Completed·BBoston Pharmaceuticals·Phase 1·NCT04221906·15 enrolled

Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test

Completed·PPrism Pharma Co., Ltd.·Phase 1/2·NCT02432027·14 enrolled

Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis

Completed·LLipidor AB·Phase 1/2·NCT05488990·24 enrolled

Show 1 more trial

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

Completed· Pfizer logo

Pfizer·Phase 1·NCT02193815·15 enrolled

Psoriasis Vulgaris3 trials

Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris

Completed·CCircassia Limited·Phase 1·NCT01743118·24 enrolled

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

Completed· LEO Pharma logo

LEO Pharma·Phase 1·NCT01580488·24 enrolled

An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris

Completed· LEO Pharma logo

LEO Pharma·Phase 1·NCT01466478·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Daivonex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daivonex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daivonex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LEO Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LEO Pharma

Daivonex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis4 trials

Psoriasis Vulgaris3 trials

References

Drug Info

Quick Facts

Related News